Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report

BMC Cardiovasc Disord. 2021 Aug 4;21(1):375. doi: 10.1186/s12872-021-02183-3.


Background: Half of U.S. adults have received at least one dose of the COVID-19 vaccines produced by either Pfizer, Moderna, or Johnson and Johnson, which represents a major milestone in the ongoing pandemic. Given the emergency use authorizations for these vaccines, their side effects and safety were assessed over a compressed time period. Hence, ongoing monitoring for vaccine-related adverse events is imperative for a full understanding and delineation of their safety profile.

Case presentation: An 22-year-old Caucasian male presented to our hospital center complaining of pleuritic chest pain. Six months prior he had a mild case of COVID-19, but was otherwise healthy. He had received his first dose of the Moderna vaccine three days prior to developing symptoms. Laboratory analysis revealed a markedly elevated troponin and multiple imaging modalities during his hospitalization found evidence of wall motion abnormalities consistent with a diagnosis of perimyocarditis. He was started on aspirin and colchicine with marked improvement of his symptoms prior to discharge.

Conclusions: We present a case of perimyocarditis that was temporally related to COVID-19 mRNA vaccination in an young male with prior COVID-19 infection but otherwise healthy. Our case report highlights an albeit rare but important adverse event for clinicians to be aware of. It also suggests a possible mechanism for the development of myocardial injury in our patient.

Keywords: COVID-19; Cardiac MRI; Case report; ECG; Myopericarditis.

Publication types

  • Case Reports
  • Video-Audio Media

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Anti-Inflammatory Agents / therapeutic use
  • Aspirin / therapeutic use
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / adverse effects*
  • Colchicine / therapeutic use
  • Humans
  • Immunization Schedule
  • Male
  • Myocarditis / chemically induced*
  • Myocarditis / diagnostic imaging
  • Myocarditis / drug therapy
  • Myocarditis / physiopathology
  • Recovery of Function
  • Treatment Outcome
  • Young Adult


  • Anti-Inflammatory Agents
  • COVID-19 Vaccines
  • 2019-nCoV Vaccine mRNA-1273
  • Aspirin
  • Colchicine